Pacific Sun Financial Corp Lowers Stock Holdings in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Pacific Sun Financial Corp decreased its position in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) by 4.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,285 shares of the company’s stock after selling 400 shares during the period. Pacific Sun Financial Corp’s holdings in SPDR S&P Pharmaceuticals ETF were worth $295,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Bank Hapoalim BM raised its position in SPDR S&P Pharmaceuticals ETF by 3.2% during the third quarter. Bank Hapoalim BM now owns 28,170 shares of the company’s stock valued at $1,007,000 after purchasing an additional 880 shares in the last quarter. Oliver Luxxe Assets LLC raised its position in SPDR S&P Pharmaceuticals ETF by 7.1% during the third quarter. Oliver Luxxe Assets LLC now owns 6,898 shares of the company’s stock valued at $244,000 after purchasing an additional 460 shares in the last quarter. Royal Bank of Canada raised its position in SPDR S&P Pharmaceuticals ETF by 67.1% during the second quarter. Royal Bank of Canada now owns 29,451 shares of the company’s stock valued at $1,174,000 after purchasing an additional 11,830 shares in the last quarter. Susquehanna International Group LLP raised its position in SPDR S&P Pharmaceuticals ETF by 29.5% during the second quarter. Susquehanna International Group LLP now owns 30,570 shares of the company’s stock valued at $1,218,000 after purchasing an additional 6,970 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in SPDR S&P Pharmaceuticals ETF during the second quarter valued at about $706,000.

NYSEARCA XPH traded up $0.62 during trading hours on Friday, reaching $38.80. 40,943 shares of the stock traded hands, compared to its average volume of 66,542. The stock has a 50 day simple moving average of $37.04 and a two-hundred day simple moving average of $37.75. SPDR S&P Pharmaceuticals ETF has a 1 year low of $34.37 and a 1 year high of $44.21.

SPDR S&P Pharmaceuticals ETF Profile

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Diversification Important in Investing

Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH).

Institutional Ownership by Quarter for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.